Princeton Global Asset Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Princeton Global Asset Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,500	Closed	-$11K	–	604
2022 Q1	$11K	Hold	1,500	–	–	﹤0.01%	439
2021 Q4	$15K	Hold	1,500	–	–	﹤0.01%	367
2021 Q3	$20K	Hold	1,500	–	–	0.01%	341
2021 Q2	$33K	Hold	1,500	–	–	0.01%	294
2021 Q1	$36K	Buy	1,500 +1,000	+200%	+$23.2K	0.01%	267
2020 Q4	$9K	Buy	+500	New	+$7.47K	﹤0.01%	399

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Princeton Global Asset Management's GTHX Position: Q2 2022 in Review

Princeton Global Asset Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2022, closing a stake of 1,500 shares — an estimated $11K sold.

Princeton Global Asset Management first reported a position in GTHX in Q4 2020 and held it in 6 quarters. The position peaked at $36K in Q1 2021. 98 funds tracked by Wall St. Rank hold GTHX as of Q2 2022.

Princeton Global Asset Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Princeton Global Asset Management sold 1,500 G1 Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $11K.
Princeton Global Asset Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Princeton Global Asset Management's G1 Therapeutics, Inc. Common Stock position peaked at $36K in Q1 2021.
98 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Princeton Global Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.